Allogeneic stem cell transplantation for myelodysplastic syndromes: critical for cure?
until further notice
SourceClinical Lymphoma Myeloma & Leukemia, 11 Suppl 1, (2011), pp. S46-8
Article / Letter to editor
Display more detailsDisplay less details
Clinical Lymphoma Myeloma & Leukemia
vol. 11 Suppl 1
SubjectONCOL 3: Translational research NCMLS 2: Immune Regulation
Allogeneic stem cell transplantation (SCT) is the treatment of choice for young patients (age </= 55 years) with myelodysplastic syndromes (MDS) characterized by poor-risk or intermediate-risk cytogenetics, who have a histocompatible related or unrelated donor. For patients who lack an human leukocyte antigen-compatible donor, autologous SCT, or chemotherapy may be good alternatives for those with MDS and with good-risk cytogenetic characteristics. Iron toxicity is an underestimated cause of hematopoietic stem cell transplantation (HSCT) treatment-related mortality. The pathogenesis, diagnosis, and monitoring of iron-induced organ damage are currently topics of investigation. Prospective studies on the prevention or treatment of iron toxicity before HSCT and/or after HSCT are necessary.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.